Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Recipient : Biovaxys
Deal Size : Undisclosed
Deal Type : Collaboration
BioVaxys & Sona Nanotech Enter Research Collaboration
Details : Through the collaboration, BioVaxys will leverage it's DPX Immune Educating Platform in combination with Sona’s Targeted Hyperthermia Therapy to treat solid tumors.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
May 07, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Recipient : Biovaxys
Deal Size : Undisclosed
Deal Type : Collaboration